Putting Women's Healthy First || Hormone Replacement Therapy

Hello! I'm Dr. Dorothy Fink, an endocrinologist and deputy director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health, part of HHS, here to share the latest major announcement from the Trump administration in support of women's health. Women should have clear answers about hormone therapy and better access to treatments that can improve our lives. Under the leadership of President Trump, First Lady Melania Trump, and Secretary Kennedy, the Health and Human Services Department is making that a reality. Today, the FDA approved updated labeling for three additional menopausal hormone therapy products, all estradiol patches. The changes remove outdated black box warning statements about cardiovascular disease, breast cancer, and probable dementia. For years, these overly broad warnings held doctors back from prescribing them for menopausal treatment and held women back from having better-informed conversations with medical professionals. The Trump administration is changing that to help provide women with better care. HHS is working with manufacturers to improve access. Estrogen patch production has doubled over the past year and the FDA continues to monitor supply and do everything possible to support manufacturers to increase supply. And patches are one of many options. Hormone therapy can also include estrogen pills, gels, creams, and vaginal estrogen. The right option depends on the woman and the symptoms being treated. We're also working directly with sponsors to make over-the-counter vaginal estrogen products available. The Trump Administration's goal is to help women get the treatment that is right for us. We deserve clear information, informed choices, and access to better care. Women deserve to be heard, and the Trump Administration is listening.